ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Our drug candidates target specific chemokines or chemo-attractant receptors, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. Our goal is to discover, develop and commercialize therapeutics with distinct advantages over currently marketed therapies in our disease areas of focus, thereby maximizing shareholder value.
10:31 AM ET on Mar 12, 2014
Delayed at least 20 minutes.
Provided by eSignal.
Mar 3, 2014
ChemoCentryx to Hold Fourth Quarter and Year-End 2013 Financial Results Conference Call on Thursday, March 13, 2014
Feb 25, 2014
ChemoCentryx to Present at the Cowen and Company 34th Annual Health Care Conference
Jan 8, 2014
ChemoCentryx to Present at the 32nd Annual J.P. Morgan Healthcare Conference
View all »Events & Presentations
Mar 13, 2014 at 5:00 PM ET
ChemoCentryx, Inc. Fourth Quarter 2013 Financial Results Conference Call
^ Return to Top